Chao Y - Search Results

1

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. Llovet JM, et al. Among authors: chao y. J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980090 Clinical Trial.

2

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Ajani JA, et al. Among authors: chao y. J Clin Oncol. 2005 Aug 20;23(24):5660-7. doi: 10.1200/JCO.2005.17.376. J Clin Oncol. 2005. PMID: 16110025 Clinical Trial.

3

Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma.

Shiah HS, Chao Y, Chen LT, Yao TJ, Huang JD, Chang JY, Chen PJ, Chuang TR, Chin YH, Whang-Peng J, Liu TW. Shiah HS, et al. Among authors: chao y. Cancer Chemother Pharmacol. 2006 Nov;58(5):654-64. doi: 10.1007/s00280-006-0203-z. Epub 2006 Mar 7. Cancer Chemother Pharmacol. 2006. PMID: 16520988 Clinical Trial.

4

Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.

Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E; V-325 Study Group. Ajani JA, et al. Among authors: chao y. J Clin Oncol. 2007 Aug 1;25(22):3205-9. doi: 10.1200/JCO.2006.10.4968. J Clin Oncol. 2007. PMID: 17664467 Clinical Trial.

5

A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma.

Chen JS, Chao Y, Bang YJ, Roca E, Chung HC, Palazzo F, Kim YH, Myrand SP, Mullaney BP, Shen LJ, Linn C. Chen JS, et al. Among authors: chao y. Anticancer Drugs. 2010 Sep;21(8):777-84. doi: 10.1097/CAD.0b013e32833cfbca. Anticancer Drugs. 2010. PMID: 20634689 Clinical Trial.

6

Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.

Hsu C, Yang TS, Huo TI, Hsieh RK, Yu CW, Hwang WS, Hsieh TY, Huang WT, Chao Y, Meng R, Cheng AL. Hsu C, et al. Among authors: chao y. J Hepatol. 2012 May;56(5):1097-1103. doi: 10.1016/j.jhep.2011.12.013. Epub 2012 Jan 13. J Hepatol. 2012. PMID: 22245891 Clinical Trial.

7

Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial.

Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY, Chao Y. Chung YH, et al. Among authors: chao y. Int J Cancer. 2013 May 15;132(10):2448-58. doi: 10.1002/ijc.27925. Epub 2012 Nov 28. Int J Cancer. 2013. PMID: 23129123 Free article. Clinical Trial.

8

Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).

Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL. Park JW, et al. Among authors: chao y. Liver Int. 2013 Mar;33(3):327-37. doi: 10.1111/liv.12083. Epub 2013 Jan 18. Liver Int. 2013. PMID: 23331661 Review.

9

Second primary cancers in patients with hepatocellular carcinoma: a nationwide cohort study in Taiwan.

Wu WC, Chen YT, Hwang CY, Su CW, Li SY, Chen TJ, Liu CJ, Kao WY, Chao Y, Lin HC, Wu JC. Wu WC, et al. Among authors: chao y. Liver Int. 2013 Apr;33(4):616-23. doi: 10.1111/liv.12103. Epub 2013 Jan 20. Liver Int. 2013. PMID: 23331767

10

Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation.

Chen PH, Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Huo TI, Huang YH, Wu WC, Chao Y, Lin HC, Wu JC. Chen PH, et al. Among authors: chao y. Ann Hepatol. 2013 Mar-Apr;12(2):263-73. Ann Hepatol. 2013. PMID: 23396738 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,347 results

Search Page